Andrew Conrad Ph.D Overview

  • Primary Position
  • General Partner

  • Primary Industry
  • Healthcare

  • Active Board Seats
  • 1

  • Med. Deal Size

  • Med. Valuation

Andrew Conrad Ph.D General Information

Biography

Dr. Andrew Conrad serves as General Partner at S32. Dr. Conrad serves as Board Member at Genalyte. Dr. Andrew Conrad is a Co-Founder of Verily Life Sciences. He serves as a Board Member at Genalyte. He also serves as a Board Member at Genalyte. He oversees an integrated team of engineers, scientists, designers, and medical experts working on a wide spectrum of healthcare-related projects. He was also the Co-Founder and served as the Chief Scientific Officer at the National Genetics Institute. Formerly the chief scientific officer of LabCorp, he is a cell biologist with a doctorate from UCLA. He has always been passionate about the early detection and prevention of disease. He co-founded the National Genetics Institute, which developed the first cost-effective test to screen for HIV in the blood supply. He also served on the Scientific Advisory Board of Medicxi's funds. He is a Working Group Member on the Precision Medicine Initiative and a member of the UCSF-Stanford Center of Excellence in Regulatory Science and Innovation (CERSI) Scientific Advisory Board.

Contact Information

Primary Position
General Partner, S32
Education
University of California, Los Angeles (UCLA), Ph.D. (Doctor of Philosophy)
Gender
Male
Phone
+1 (650)
Address
  • 169 University Avenue
  • CA 94301
  • United States
+1 (650)

Andrew Conrad Ph.D Positions (2)

Firm name Firm type Title Location Industry Since
S32 Investor General Partner CA Venture Capital
Verily Life Sciences Company Co-Founder Dallas, TX Monitoring Equipment

Andrew Conrad Ph.D Board Seats (2)

Company Industry Ownership Status Financing Status Location Since
Genalyte Laboratory Services (Healthcare) Privately Held (backing) Venture Capital-Backed San Diego, CA
SynapDx Laboratory Services (Healthcare) Out of Business Formerly VC-backed Lexington, MA

Andrew Conrad Ph.D Lead Partner on Deals (3)

Company Deal Date Deal Type Deal Size Deal Status Industry Location
Genalyte 06-Mar-2023 Later Stage VC (Series C2) Completed Laboratory Services (Healthcare) San Diego, CA
Granular Insurance Company 29-Sep-2022 Completed Other Insurance South San Francisco, CA
Genalyte 11-Jan-2021 Completed Laboratory Services (Healthcare) San Diego, CA

Andrew Conrad Ph.D Network (48)

Board Members (24)

Name Company Representing Location From
Daniel O'Day Flatiron Roche New York, NY
Vijit Sabnis Ph.D Genalyte Khosla Ventures San Diego, CA
Genalyte Genalyte San Diego, CA
Genalyte Genalyte San Diego, CA
SynapDx Self Lexington, MA

Portfolio Executives (24)

Name Company Role Deal date Location
Brett Brown Genalyte Vice President, Finance 06-Mar-2023 San Diego, CA
Sam Rutten Genalyte Vice President of Finance and People Operations 06-Mar-2023 San Diego, CA
Genalyte Head of Sales & Marketing 06-Mar-2023 San Diego, CA
Genalyte Founder & Board Member 06-Mar-2023 San Diego, CA
Genalyte Vice President of Clinical Assay Development 06-Mar-2023 San Diego, CA

Andrew Conrad Ph.D FAQs

  • Who is Andrew Conrad Ph.D?

    Dr. Andrew Conrad serves as General Partner at S32.

  • How much does Andrew Conrad Ph.D typically invest?

    Andrew Conrad Ph.D's median deal size is .

  • What is Andrew Conrad Ph.D’s main position?

    Andrew Conrad Ph.D’s primary position is General Partner.

  • How many active board seats does Andrew Conrad Ph.D hold?

    Andrew Conrad Ph.D holds 2 board seats including Genalyte and SynapDx.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »